|
|
|
☒
|
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|
☐
|
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|
Securities registered pursuant to Section 12(b) of the Securities Exchange Act of 1934:
|
||
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
Common Stock
|
CDLX
|
NASDAQ
|
Large accelerated filer
|
|
☐
|
|
|
Accelerated filer
|
|
☒
|
Non-accelerated filer
|
|
☐
|
|
|
Smaller reporting company
|
|
☒
|
|
|
|
|
|
Emerging growth company
|
|
☒
|
|
|
|
Page
|
PART I.
|
FINANCIAL INFORMATION
|
|
Item 1.
|
||
|
||
|
||
|
||
|
||
|
||
|
||
Item 2.
|
||
Item 3.
|
||
Item 4.
|
||
PART II.
|
OTHER INFORMATION
|
|
Item 1.
|
||
Item 1A.
|
||
Item 2.
|
||
Item 6.
|
||
CARDLYTICS, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED)
(Amounts in thousands, except par value amounts)
|
|||||||
|
December 31, 2018
|
|
September 30, 2019
|
||||
Assets
|
|
|
|
||||
Current assets:
|
|
|
|
||||
Cash and cash equivalents
|
$
|
39,623
|
|
|
$
|
95,184
|
|
Restricted cash
|
20,247
|
|
|
246
|
|
||
Accounts receivable, net
|
58,125
|
|
|
61,691
|
|
||
Other receivables
|
2,417
|
|
|
3,634
|
|
||
Prepaid expenses and other assets
|
3,956
|
|
|
5,320
|
|
||
Total current assets
|
124,368
|
|
|
166,075
|
|
||
Long-term assets:
|
|
|
|
|
|
||
Property and equipment, net
|
10,230
|
|
|
12,125
|
|
||
Intangible assets, net
|
370
|
|
|
375
|
|
||
Capitalized software development costs, net
|
1,625
|
|
|
3,099
|
|
||
Deferred FI implementation costs, net
|
15,877
|
|
|
10,235
|
|
||
Other long-term assets, net
|
1,293
|
|
|
1,338
|
|
||
Total assets
|
$
|
153,763
|
|
|
$
|
193,247
|
|
Liabilities and stockholders' equity
|
|
|
|
||||
Current liabilities:
|
|
|
|
||||
Accounts payable
|
$
|
2,099
|
|
|
$
|
1,946
|
|
Accrued liabilities:
|
|
|
|
||||
Accrued compensation
|
5,936
|
|
|
6,944
|
|
||
Accrued expenses
|
4,388
|
|
|
3,906
|
|
||
FI Share liability
|
27,656
|
|
|
33,697
|
|
||
Consumer Incentive liability
|
11,476
|
|
|
15,873
|
|
||
Deferred billings
|
346
|
|
|
745
|
|
||
Current portion of long-term debt
|
21
|
|
|
23
|
|
||
Total current liabilities
|
51,922
|
|
|
63,134
|
|
||
Long-term liabilities:
|
|
|
|
||||
Deferred liabilities
|
3,173
|
|
|
2,773
|
|
||
Long-term debt, net of current portion
|
46,693
|
|
|
19
|
|
||
Total liabilities
|
101,788
|
|
|
65,926
|
|
||
Stockholders’ equity:
|
|
|
|
||||
Common stock, $0.0001 par value—100,000 shares authorized and 22,466 and 25,664 shares issued and outstanding as of December 31, 2018 and September 30, 2019, respectively
|
7
|
|
|
8
|
|
||
Additional paid-in capital
|
371,463
|
|
|
466,737
|
|
||
Accumulated other comprehensive income
|
1,992
|
|
|
2,634
|
|
||
Accumulated deficit
|
(321,487
|
)
|
|
(342,058
|
)
|
||
Total stockholders’ equity
|
51,975
|
|
|
127,321
|
|
||
Total liabilities and stockholders’ equity
|
$
|
153,763
|
|
|
$
|
193,247
|
|
|
Three Months Ended September 30,
|
|
Nine Months Ended September 30,
|
||||||||||||
|
2018
|
|
2019
|
|
2018
|
|
2019
|
||||||||
Revenue
|
$
|
34,582
|
|
|
$
|
56,419
|
|
|
$
|
102,865
|
|
|
$
|
141,137
|
|
Costs and expenses:
|
|
|
|
|
|
|
|
||||||||
FI Share and other third-party costs
|
17,982
|
|
|
32,470
|
|
|
59,149
|
|
|
79,094
|
|
||||
Delivery costs
|
3,007
|
|
|
3,070
|
|
|
7,509
|
|
|
9,686
|
|
||||
Sales and marketing expense
|
9,452
|
|
|
11,074
|
|
|
27,915
|
|
|
31,458
|
|
||||
Research and development expense
|
4,097
|
|
|
3,018
|
|
|
12,444
|
|
|
8,741
|
|
||||
General and administration expense
|
7,925
|
|
|
12,218
|
|
|
23,486
|
|
|
27,558
|
|
||||
Depreciation and amortization expense
|
777
|
|
|
1,167
|
|
|
2,471
|
|
|
3,181
|
|
||||
Total costs and expenses
|
43,240
|
|
|
63,017
|
|
|
132,974
|
|
|
159,718
|
|
||||
Operating loss
|
(8,658
|
)
|
|
(6,598
|
)
|
|
(30,109
|
)
|
|
(18,581
|
)
|
||||
Other income (expense):
|
|
|
|
|
|
|
|
||||||||
Interest expense, net
|
(254
|
)
|
|
(218
|
)
|
|
(2,995
|
)
|
|
(860
|
)
|
||||
Change in fair value of warrant liabilities, net
|
801
|
|
|
—
|
|
|
(6,760
|
)
|
|
—
|
|
||||
Other expense
|
(257
|
)
|
|
(931
|
)
|
|
(1,612
|
)
|
|
(1,130
|
)
|
||||
Total other income (expense)
|
290
|
|
|
(1,149
|
)
|
|
(11,367
|
)
|
|
(1,990
|
)
|
||||
Loss before income taxes
|
(8,368
|
)
|
|
(7,747
|
)
|
|
(41,476
|
)
|
|
(20,571
|
)
|
||||
Net loss
|
(8,368
|
)
|
|
(7,747
|
)
|
|
(41,476
|
)
|
|
(20,571
|
)
|
||||
Adjustments to the carrying value of preferred stock
|
—
|
|
|
—
|
|
|
(157
|
)
|
|
—
|
|
||||
Net loss attributable to common stockholders
|
$
|
(8,368
|
)
|
|
$
|
(7,747
|
)
|
|
$
|
(41,633
|
)
|
|
$
|
(20,571
|
)
|
Net loss per share attributable to common stockholders, basic and diluted
|
$
|
(0.40
|
)
|
|
$
|
(0.33
|
)
|
|
$
|
(2.29
|
)
|
|
$
|
(0.90
|
)
|
Weighted-average common shares outstanding, basic and diluted
|
20,970
|
|
|
23,561
|
|
|
18,150
|
|
|
22,936
|
|
|
Three Months Ended September 30,
|
|
Nine Months Ended September 30,
|
||||||||||||
|
2018
|
|
2019
|
|
2018
|
|
2019
|
||||||||
Net loss
|
$
|
(8,368
|
)
|
|
$
|
(7,747
|
)
|
|
$
|
(41,476
|
)
|
|
$
|
(20,571
|
)
|
Other comprehensive income:
|
|
|
|
|
|
|
|
||||||||
Foreign currency translation adjustments
|
202
|
|
|
565
|
|
|
574
|
|
|
642
|
|
||||
Total comprehensive loss
|
$
|
(8,166
|
)
|
|
$
|
(7,182
|
)
|
|
$
|
(40,902
|
)
|
|
$
|
(19,929
|
)
|
|
|
|
Additional
Paid-In
Capital
|
|
Accumulated
Other
Comprehensive
Income
|
|
Accumulated
Deficit
|
|
Total
|
|||||||||||||
|
Common Stock
|
|
||||||||||||||||||||
|
Shares
|
|
Amount
|
|
||||||||||||||||||
Balance – December 31, 2018
|
22,466
|
|
|
$
|
7
|
|
|
$
|
371,463
|
|
|
$
|
1,992
|
|
|
$
|
(321,487
|
)
|
|
$
|
51,975
|
|
Exercise of common stock options
|
215
|
|
|
—
|
|
|
2,850
|
|
|
—
|
|
|
—
|
|
|
2,850
|
|
|||||
Exercise of common stock warrants
|
821
|
|
|
—
|
|
|
17,659
|
|
|
—
|
|
|
—
|
|
|
17,659
|
|
|||||
Stock-based compensation
|
—
|
|
|
—
|
|
|
12,292
|
|
|
—
|
|
|
—
|
|
|
12,292
|
|
|||||
Settlement of restricted stock
|
164
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|||||
Issuance of common stock
|
1,904
|
|
|
1
|
|
|
61,308
|
|
|
—
|
|
|
—
|
|
|
61,309
|
|
|||||
Issuance of common stock pursuant to the ESPP
|
94
|
|
|
—
|
|
|
1,165
|
|
|
—
|
|
|
—
|
|
|
1,165
|
|
|||||
Other comprehensive income
|
—
|
|
|
—
|
|
|
—
|
|
|
642
|
|
|
—
|
|
|
642
|
|
|||||
Net loss
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
(20,571
|
)
|
|
(20,571
|
)
|
|||||
Balance – September 30, 2019
|
25,664
|
|
|
$
|
8
|
|
|
$
|
466,737
|
|
|
$
|
2,634
|
|
|
$
|
(342,058
|
)
|
|
$
|
127,321
|
|
|
|
|
Additional Paid-In-Capital
|
|
Accumulated Other Comprehensive Income
|
|
Accumulated Deficit
|
|
Total
|
|||||||||||||
|
Common Stock
|
|
||||||||||||||||||||
|
Shares
|
|
Amount
|
|
||||||||||||||||||
Balance – June 30, 2019
|
22,828
|
|
|
$
|
7
|
|
|
$
|
378,773
|
|
|
$
|
2,069
|
|
|
$
|
(334,311
|
)
|
|
$
|
46,538
|
|
Exercise of common stock options
|
104
|
|
|
—
|
|
|
1,502
|
|
|
—
|
|
|
—
|
|
|
1,502
|
|
|||||
Exercise of common stock warrants
|
821
|
|
|
—
|
|
|
17,659
|
|
|
—
|
|
|
—
|
|
|
17,659
|
|
|||||
Stock-based compensation
|
—
|
|
|
—
|
|
|
7,495
|
|
|
—
|
|
|
—
|
|
|
7,495
|
|
|||||
Settlement of restricted stock
|
7
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|||||
Issuance of common stock
|
1,904
|
|
|
1
|
|
|
61,308
|
|
|
—
|
|
|
—
|
|
|
61,309
|
|
|||||
Other comprehensive income
|
—
|
|
|
—
|
|
|
—
|
|
|
565
|
|
|
—
|
|
|
565
|
|
|||||
Net loss
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
(7,747
|
)
|
|
(7,747
|
)
|
|||||
Balance – September 30, 2019
|
25,664
|
|
|
$
|
8
|
|
|
$
|
466,737
|
|
|
$
|
2,634
|
|
|
$
|
(342,058
|
)
|
|
$
|
127,321
|
|
|
|
|
|
|
Additional Paid-In-Capital
|
|
Accumulated Other Comprehensive Income
|
|
Accumulated Deficit
|
|
Total
|
|||||||||||
|
Common Stock
|
|
|
|
|
|||||||||||||||||
|
Shares
|
|
Amount
|
|
|
|
|
|||||||||||||||
Balance – December 31, 2017
|
3,439
|
|
|
$
|
—
|
|
|
$
|
58,693
|
|
|
$
|
1,066
|
|
|
(268,445
|
)
|
|
$
|
(208,686
|
)
|
|
Exercise of common stock options
|
329
|
|
|
—
|
|
|
1,799
|
|
|
—
|
|
|
—
|
|
|
1,799
|
|
|||||
Exercise of common stock warrants
|
1,142
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|||||
Stock-based compensation
|
—
|
|
|
—
|
|
|
16,968
|
|
|
—
|
|
|
—
|
|
|
16,968
|
|
|||||
Settlement of restricted stock
|
37
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|||||
Issuance of common stock
|
5,821
|
|
|
1
|
|
|
66,100
|
|
|
—
|
|
|
—
|
|
|
66,101
|
|
|||||
Vesting of common stock warrants
|
—
|
|
|
—
|
|
|
17,774
|
|
|
—
|
|
|
—
|
|
|
17,774
|
|
|||||
Conversion of preferred stock to common stock
|
10,643
|
|
|
6
|
|
|
196,588
|
|
|
—
|
|
|
—
|
|
|
196,594
|
|
|||||
Conversion of preferred stock warrants to common stock warrants
|
—
|
|
|
—
|
|
|
1,736
|
|
|
—
|
|
|
—
|
|
|
1,736
|
|
|||||
Accretion of redeemable convertible preferred stock to redemption value
|
—
|
|
|
—
|
|
|
(157
|
)
|
|
—
|
|
|
—
|
|
|
(157
|
)
|
|||||
Other comprehensive income
|
—
|
|
|
—
|
|
|
—
|
|
|
574
|
|
|
—
|
|
|
574
|
|
|||||
Net loss
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
(41,476
|
)
|
|
(41,476
|
)
|
|||||
Balance – September 30, 2018
|
21,411
|
|
|
$
|
7
|
|
|
$
|
359,501
|
|
|
$
|
1,640
|
|
|
$
|
(309,921
|
)
|
|
$
|
51,227
|
|
|
|
|
|
|
Additional Paid-In-Capital
|
|
Accumulated Other Comprehensive Income
|
|
Accumulated Deficit
|
|
Total
|
|||||||||||
|
Common Stock
|
|
|
|
|
|||||||||||||||||
|
Shares
|
|
Amount
|
|
|
|
|
|||||||||||||||
Balance – June 30, 2018
|
20,316
|
|
|
$
|
7
|
|
|
$
|
336,874
|
|
|
$
|
1,438
|
|
|
$
|
(301,553
|
)
|
|
$
|
36,766
|
|
Exercise of common stock options
|
265
|
|
|
—
|
|
|
1,655
|
|
|
—
|
|
|
—
|
|
|
1,655
|
|
|||||
Exercise of common stock warrants
|
793
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|||||
Stock-based compensation
|
—
|
|
|
—
|
|
|
5,717
|
|
|
—
|
|
|
—
|
|
|
5,717
|
|
|||||
Settlement of restricted stock
|
37
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|||||
Vesting of common stock warrants
|
—
|
|
|
—
|
|
|
15,255
|
|
|
—
|
|
|
—
|
|
|
15,255
|
|
|||||
Other comprehensive income
|
—
|
|
|
—
|
|
|
—
|
|
|
202
|
|
|
—
|
|
|
202
|
|
|||||
Net loss
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
(8,368
|
)
|
|
(8,368
|
)
|
|||||
Balance – September 30, 2018
|
21,411
|
|
|
$
|
7
|
|
|
$
|
359,501
|
|
|
$
|
1,640
|
|
|
$
|
(309,921
|
)
|
|
$
|
51,227
|
|
|
Nine Months Ended September 30,
|
||||||
|
2018
|
|
2019
|
||||
Operating activities
|
|
|
|
||||
Net loss
|
$
|
(41,476
|
)
|
|
$
|
(20,571
|
)
|
Adjustments to reconcile net loss to net cash used in operating activities:
|
|
|
|
||||
Depreciation and amortization
|
2,471
|
|
|
3,181
|
|
||
Amortization of financing costs charged to interest expense
|
255
|
|
|
72
|
|
||
Accretion of debt discount and non-cash interest expense
|
2,326
|
|
|
—
|
|
||
Stock-based compensation expense
|
16,968
|
|
|
12,266
|
|
||
Change in fair value of warrant liabilities, net
|
6,760
|
|
|
—
|
|
||
Other non-cash expense, net
|
4,136
|
|
|
2,434
|
|
||
Amortization of deferred FI implementation costs
|
1,136
|
|
|
2,173
|
|
||
Settlement of paid-in-kind interest
|
(8,353
|
)
|
|
—
|
|
||
Change in operating assets and liabilities:
|
|
|
|
||||
Accounts receivable
|
10,883
|
|
|
(5,789
|
)
|
||
Prepaid expenses and other assets
|
(1,797
|
)
|
|
(1,368
|
)
|
||
Deferred FI implementation costs
|
(5,750
|
)
|
|
—
|
|
||
Recovery of deferred FI implementation costs
|
4,036
|
|
|
3,469
|
|
||
Accounts payable
|
221
|
|
|
(401
|
)
|
||
Other accrued expenses
|
24
|
|
|
1,453
|
|
||
FI Share liability
|
(3,728
|
)
|
|
6,041
|
|
||
Customer Incentive liability
|
(2,412
|
)
|
|
4,397
|
|
||
Net cash (used in) from operating activities
|
(14,300
|
)
|
|
7,357
|
|
||
Investing activities
|
|
|
|
||||
Acquisition of property and equipment
|
(3,190
|
)
|
|
(4,561
|
)
|
||
Acquisition of patents
|
(14
|
)
|
|
(14
|
)
|
||
Capitalized software development costs
|
(981
|
)
|
|
(1,836
|
)
|
||
Net cash used in investing activities
|
(4,185
|
)
|
|
(6,411
|
)
|
||
Financing activities
|
|
|
|
||||
Proceeds from issuance of debt
|
47,435
|
|
|
—
|
|
||
Principal payments of debt
|
(52,475
|
)
|
|
(46,692
|
)
|
||
Proceeds from issuance of common stock
|
72,179
|
|
|
81,922
|
|
||
Equity issuance costs
|
(1,949
|
)
|
|
(38
|
)
|
||
Debt issuance costs
|
(48
|
)
|
|
(143
|
)
|
||
Net cash from financing activities
|
65,142
|
|
|
35,049
|
|
||
Effect of exchange rates on cash, cash equivalents and restricted cash
|
(107
|
)
|
|
(435
|
)
|
||
Net increase in cash, cash equivalents and restricted cash
|
46,550
|
|
|
35,560
|
|
||
Cash, cash equivalents, and restricted cash — Beginning of period
|
21,262
|
|
|
59,870
|
|
||
Cash, cash equivalents, and restricted cash — End of period
|
$
|
67,812
|
|
|
$
|
95,430
|
|
|
Nine Months Ended September 30,
|
||||||
|
2018
|
|
2019
|
||||
Reconciliation of cash, cash equivalents and restricted cash to the condensed consolidated balance sheet:
|
|
|
|
||||
Cash and cash equivalents
|
$
|
47,812
|
|
|
$
|
95,184
|
|
Restricted cash
|
20,000
|
|
|
246
|
|
||
Total cash, cash equivalents and restricted cash — End of period
|
$
|
67,812
|
|
|
$
|
95,430
|
|
|
|
|
|
||||
Supplemental schedule of non-cash investing and financing activities:
|
|
|
|
||||
Cash paid for interest
|
$
|
9,158
|
|
|
$
|
1,259
|
|
Amounts accrued for property and equipment
|
$
|
1,697
|
|
|
$
|
991
|
|
Amounts accrued for capitalized software development costs
|
$
|
9
|
|
|
$
|
—
|
|
•
|
CPS. Our primary pricing model is CPS, which we created to meet the media buying preferences of marketers. We generate revenue by charging a percentage, which we refer to as the CPS Rate, of all purchases from the marketer by consumers (1) who are served marketing and (2) subsequently make a purchase from the marketer during the campaign period, regardless of whether consumers select the marketing and thereby becomes eligible to earn the applicable Consumer Incentive. We set CPS Rates for marketers based on our expectation of the marketer’s return on spend for the relevant campaign. Additionally, we set the amount of the Consumer Incentives payable for each campaign based on our estimation of our ability to drive incremental sales for the marketer. We seek to optimize the level of Consumer Incentives to retain a greater portion of billings. However, if the amount of Consumer Incentives exceeds the amount of billings that we are paid by the applicable marketer we are still responsible for paying the total Consumer Incentive. This has occurred infrequently and has been immaterial in amount for each of the periods presented. In some instances, we may also charge the marketer the Consumer Incentive, in which case the marketer determines the level of Consumer Incentive for the campaign.
|
•
|
CPR. Under our CPR pricing model, marketers specify and fund the Consumer Incentive and pay us a separate negotiated, fixed marketing fee, which we refer to as the CPR Fee, for each purchase that we generate. We generate revenue if the consumer (1) is served marketing, (2) selects the marketing and thereby becomes eligible to earn the applicable Consumer Incentive and (3) makes a qualifying purchase from the marketer during the campaign period. We set the CPR Fee for marketers based on our estimation of the marketers’ return on spend for the relevant campaign. The CPR Fee is either a percentage of qualifying purchases or a flat amount. In some instances, we may solely charge the marketer the CPR Fee, in which case we determine the level of Consumer Incentive for the campaign.
|
|
Three Months Ended September 30,
|
|
Nine Months Ended September 30,
|
||||||||||||
|
2018
|
|
2019
|
|
2018
|
|
2019
|
||||||||
Cost per Served Sale
|
$
|
25,320
|
|
|
$
|
40,000
|
|
|
$
|
67,775
|
|
|
$
|
94,558
|
|
Cost per Redemption
|
8,236
|
|
|
15,611
|
|
|
29,447
|
|
|
43,851
|
|
||||
Other
|
1,026
|
|
|
808
|
|
|
5,643
|
|
|
2,728
|
|
||||
Revenue
|
$
|
34,582
|
|
|
$
|
56,419
|
|
|
$
|
102,865
|
|
|
$
|
141,137
|
|
•
|
identification of a contract with a customer,
|
•
|
identification of the performance obligation(s) in the contract,
|
•
|
determination of the transaction price,
|
•
|
allocation of the transaction price to the performance obligation(s) in the contract, and
|
•
|
recognition of revenue when or as the performance obligation(s) are satisfied.
|
|
December 31, 2018
|
|
September 30, 2019
|
||||
Lines of credit
|
$
|
26,677
|
|
|
$
|
—
|
|
Term loans(1)
|
19,980
|
|
|
—
|
|
||
Capital leases
|
57
|
|
|
42
|
|
||
Total debt
|
46,714
|
|
|
42
|
|
||
Less current portion of long-term debt
|
(21
|
)
|
|
(23
|
)
|
||
Long-term debt, net of current portion
|
$
|
46,693
|
|
|
$
|
19
|
|
(1)
|
Net of unamortized debt issuance costs of $20 and $0 as of December 31, 2018 and September 30, 2019, respectively.
|
Years Ending December 31,
|
Debt
|
|
Capital leases
|
|
Total debt
|
||||||
2019 (remainder of year)
|
$
|
—
|
|
|
$
|
5
|
|
|
$
|
5
|
|
2020
|
—
|
|
|
24
|
|
|
24
|
|
|||
2021
|
—
|
|
|
13
|
|
|
13
|
|
|||
Total debt
|
$
|
—
|
|
|
$
|
42
|
|
|
$
|
42
|
|
|
Three Months Ended
September 30, |
|
Nine Months Ended
September 30, |
||||||||||||
|
2018
|
|
2019
|
|
2018
|
|
2019
|
||||||||
Delivery costs
|
$
|
203
|
|
|
$
|
176
|
|
|
$
|
471
|
|
|
$
|
539
|
|
Sales and marketing expense
|
1,939
|
|
|
1,432
|
|
|
5,550
|
|
|
3,091
|
|
||||
Research and development expense
|
915
|
|
|
638
|
|
|
3,141
|
|
|
1,204
|
|
||||
General and administration expense
|
2,666
|
|
|
5,240
|
|
|
7,806
|
|
|
7,432
|
|
||||
Total stock-based compensation expense
|
$
|
5,723
|
|
|
$
|
7,486
|
|
|
$
|
16,968
|
|
|
$
|
12,266
|
|
|
Shares
(in thousands)
|
|
Weighted-Average Exercise Price
|
|
Weighted Average Remaining Vesting Period (in years)
|
|
Aggregate Intrinsic Value(1)
(in thousands)
|
|||||
Options outstanding — December 31, 2018
|
1,774
|
|
|
$
|
20.55
|
|
|
2.01
|
|
$
|
1,214
|
|
Granted
|
39
|
|
|
20.64
|
|
|
|
|
|
|||
Exercised
|
(215
|
)
|
|
13.25
|
|
|
|
|
|
|||
Forfeited
|
(28
|
)
|
|
23.82
|
|
|
|
|
|
|||
Canceled
|
(65
|
)
|
|
22.36
|
|
|
|
|
|
|||
Options outstanding — September 30, 2019
|
1,505
|
|
|
21.46
|
|
|
1.33
|
|
$
|
18,871
|
|
|
Exercisable — September 30, 2019
|
1,195
|
|
|
$
|
20.70
|
|
|
|
|
|
(1)
|
The aggregate intrinsic value represents the total pre-tax intrinsic value based on the $10.83 and $33.52 per share closing price of our common stock as reported on the Nasdaq Global Market on December 31, 2018 and September 30, 2019, respectively, that would have been received by option holders had all in-the-money options been exercised on that date.
|
|
Shares
(in thousands)
|
|
Weighted-Average Grant Date Fair Value
|
|
Weighted-Average Remaining Vesting Period (in years)
|
|
Unamortized Compensation Costs
(in thousands)
|
|||||
Unvested — December 31, 2018
|
381
|
|
|
$
|
18.11
|
|
|
2.42
|
|
$
|
4,536
|
|
Granted
|
1,792
|
|
|
15.86
|
|
|
|
|
|
|||
Vested(1)
|
(324
|
)
|
|
14.65
|
|
|
|
|
|
|||
Forfeited
|
(112
|
)
|
|
19.02
|
|
|
|
|
|
|||
Unvested — September 30, 2019
|
1,737
|
|
|
$
|
16.38
|
|
|
3.06
|
|
$
|
21,519
|
|
(1)
|
Includes 160 RSUs that have vested but have not been settled.
|
•
|
a minimum growth rate in adjusted contribution over a trailing 12-month period,
|
•
|
a minimum number of advertisers that are billed above a specified amount over a trailing 12-month period,
|
•
|
a minimum cumulative adjusted EBITDA target over a trailing 12-month period, and
|
•
|
a minimum trailing 30-day average closing price of our common stock.
|
|
Shares
|
|
Weighted-average
exercise price
per share
|
|||
Warrants outstanding — December 31, 2018
|
868
|
|
|
$
|
21.89
|
|
Exercised
|
(821
|
)
|
|
21.89
|
|
|
Forfeited/canceled
|
(34
|
)
|
|
21.29
|
|
|
Warrants outstanding — September 30, 2019
|
13
|
|
|
$
|
23.64
|
|
|
Three Months Ended
September 30, |
|
Nine Months Ended
September 30, |
||||||||||||
|
2018
|
|
2019
|
|
2018
|
|
2019
|
||||||||
Beginning balance
|
$
|
12,425
|
|
|
$
|
12,181
|
|
|
$
|
13,625
|
|
|
$
|
15,877
|
|
Deferred costs
|
3,500
|
|
|
—
|
|
|
5,750
|
|
|
—
|
|
||||
Recoveries through FI Share
|
(1,344
|
)
|
|
(1,157
|
)
|
|
(4,036
|
)
|
|
(3,469
|
)
|
||||
Amortization
|
(378
|
)
|
|
(789
|
)
|
|
(1,136
|
)
|
|
(2,173
|
)
|
||||
Ending balance
|
$
|
14,203
|
|
|
$
|
10,235
|
|
|
$
|
14,203
|
|
|
$
|
10,235
|
|
|
September 30,
|
||||
|
2018
|
|
2019
|
||
Common stock options
|
1,862
|
|
|
1,505
|
|
Common stock warrants
|
868
|
|
|
13
|
|
Unvested restricted stock units
|
1,200
|
|
|
1,737
|
|
Common stock issuable pursuant to the ESPP
|
151
|
|
|
49
|
|
|
Three Months Ended September 30,
|
|
Nine Months Ended September 30,
|
||||||||||||
|
2018
|
|
2019
|
|
2018
|
|
2019
|
||||||||
Cardlytics Direct:
|
|
|
|
|
|
|
|
||||||||
Adjusted contribution
|
$
|
16,906
|
|
|
$
|
24,738
|
|
|
$
|
47,368
|
|
|
$
|
64,216
|
|
Plus: Adjusted FI Share and other third-party costs(1)
|
17,514
|
|
|
31,681
|
|
|
54,271
|
|
|
76,921
|
|
||||
Revenue
|
$
|
34,420
|
|
|
$
|
56,419
|
|
|
$
|
101,639
|
|
|
$
|
141,137
|
|
Other Platform Solutions:
|
|
|
|
|
|
|
|
||||||||
Adjusted contribution
|
$
|
72
|
|
|
$
|
—
|
|
|
$
|
3
|
|
|
$
|
—
|
|
Plus: Adjusted FI Share and other third-party costs(1)
|
90
|
|
|
—
|
|
|
1,223
|
|
|
—
|
|
||||
Revenue
|
$
|
162
|
|
|
$
|
—
|
|
|
$
|
1,226
|
|
|
$
|
—
|
|
Total:
|
|
|
|
|
|
|
|
||||||||
Adjusted contribution
|
$
|
16,978
|
|
|
$
|
24,738
|
|
|
$
|
47,371
|
|
|
$
|
64,216
|
|
Plus: Adjusted FI Share and other third-party costs(1)
|
17,604
|
|
|
31,681
|
|
|
55,494
|
|
|
76,921
|
|
||||
Revenue
|
$
|
34,582
|
|
|
$
|
56,419
|
|
|
$
|
102,865
|
|
|
$
|
141,137
|
|
(1)
|
Adjusted FI Share and other third-party costs presented above represents GAAP FI Share and other third-party data costs less a non-cash equity expense included in FI Share and amortization of deferred FI implementation costs, which are detailed below in our reconciliation of GAAP loss before income taxes to adjusted contribution.
|
|
Three Months Ended September 30,
|
|
Nine Months Ended September 30,
|
||||||||||||
|
2018
|
|
2019
|
|
2018
|
|
2019
|
||||||||
Adjusted contribution
|
$
|
16,978
|
|
|
$
|
24,738
|
|
|
$
|
47,371
|
|
|
$
|
64,216
|
|
Minus:
|
|
|
|
|
|
|
|
||||||||
Non-cash equity expense included in FI Share(1)
|
—
|
|
|
—
|
|
|
2,519
|
|
|
—
|
|
||||
Amortization of deferred FI implementation costs(1)
|
378
|
|
|
789
|
|
|
1,136
|
|
|
2,173
|
|
||||
Delivery costs
|
3,007
|
|
|
3,070
|
|
|
7,509
|
|
|
9,686
|
|
||||
Sales and marketing expense
|
9,452
|
|
|
11,074
|
|
|
27,915
|
|
|
31,458
|
|
||||
Research and development expense
|
4,097
|
|
|
3,018
|
|
|
12,444
|
|
|
8,741
|
|
||||
General and administration expense
|
7,925
|
|
|
12,218
|
|
|
23,486
|
|
|
27,558
|
|
||||
Depreciation and amortization expense
|
777
|
|
|
1,167
|
|
|
2,471
|
|
|
3,181
|
|
||||
Total other expense (income)
|
(290
|
)
|
|
1,149
|
|
|
11,367
|
|
|
1,990
|
|
||||
Loss before income taxes
|
$
|
(8,368
|
)
|
|
$
|
(7,747
|
)
|
|
$
|
(41,476
|
)
|
|
$
|
(20,571
|
)
|
(1)
|
Non-cash equity expense included in FI Share and amortization of deferred FI implementation costs are excluded from adjusted FI Share and other third party costs, which is shown above in our reconciliation of GAAP revenue to adjusted contribution.
|
|
Three Months Ended September 30,
|
|
Nine Months Ended September 30,
|
||||||||||||
|
2018
|
|
2019
|
|
2018
|
|
2019
|
||||||||
Revenue:
|
|
|
|
|
|
|
|
||||||||
United States
|
$
|
30,884
|
|
|
$
|
50,997
|
|
|
$
|
90,606
|
|
|
$
|
125,468
|
|
United Kingdom
|
3,698
|
|
|
5,422
|
|
|
12,259
|
|
|
15,669
|
|
||||
Total
|
$
|
34,582
|
|
|
$
|
56,419
|
|
|
$
|
102,865
|
|
|
$
|
141,137
|
|
|
December 31, 2018
|
|
September 30, 2019
|
||||
Property and equipment:
|
|
|
|
||||
United States
|
$
|
9,794
|
|
|
$
|
11,583
|
|
United Kingdom
|
436
|
|
|
384
|
|
||
India
|
$
|
—
|
|
|
$
|
158
|
|
Total
|
$
|
10,230
|
|
|
$
|
12,125
|
|
|
Three Months Ended September 30,
|
|
Change
|
|
Nine Months Ended September 30,
|
|
Change
|
||||||||||||||||||||
|
2018
|
|
2019
|
|
$
|
|
%
|
|
2018
|
|
2019
|
|
$
|
|
%
|
||||||||||||
Billings
|
$
|
48,584
|
|
|
$
|
82,792
|
|
|
$
|
34,208
|
|
|
70%
|
|
$
|
148,764
|
|
|
$
|
215,118
|
|
|
$
|
66,354
|
|
|
45%
|
Consumer Incentives
|
14,002
|
|
|
26,373
|
|
|
12,371
|
|
|
88
|
|
45,899
|
|
|
73,981
|
|
|
28,082
|
|
|
61
|
||||||
Revenue
|
34,582
|
|
|
56,419
|
|
|
21,837
|
|
|
63
|
|
102,865
|
|
|
141,137
|
|
|
38,272
|
|
|
37
|
||||||
Adjusted FI Share and other third-party costs(1)(2)
|
17,604
|
|
|
31,681
|
|
|
14,077
|
|
|
80
|
|
55,494
|
|
|
76,921
|
|
|
21,427
|
|
|
39
|
||||||
Adjusted contribution(2)
|
$
|
16,978
|
|
|
$
|
24,738
|
|
|
$
|
7,760
|
|
|
46%
|
|
$
|
47,371
|
|
|
$
|
64,216
|
|
|
$
|
16,845
|
|
|
36%
|
(1)
|
Adjusted FI Share and other third-party costs excludes a non-cash equity expense included in FI Share and amortization of deferred FI implementation costs, as detailed below in our reconciliation of GAAP gross profit to adjusted contribution.
|
(2)
|
Adjusted FI Share and other third-party costs and adjusted contribution include the impact of a $0.8 million gain during the third quarter of 2018 related to the renewal of our agreement with Lloyds, which contains certain amendments that are retroactively applied as of January 1, 2018.
|
|
Three Months Ended September 30,
|
|
Nine Months Ended September 30,
|
||||||||||||
|
2018
|
|
2019
|
|
2018
|
|
2019
|
||||||||
|
(in thousands, except ARPU)
|
||||||||||||||
FI MAUs
|
59,333
|
|
|
128,315
|
|
|
58,942
|
|
|
118,969
|
|
||||
ARPU
|
$
|
0.58
|
|
|
$
|
0.44
|
|
|
$
|
1.72
|
|
|
$
|
1.19
|
|
Billings
|
$
|
48,584
|
|
|
$
|
82,792
|
|
|
$
|
148,764
|
|
|
$
|
215,118
|
|
Adjusted contribution(1)
|
$
|
16,978
|
|
|
$
|
24,738
|
|
|
$
|
47,371
|
|
|
$
|
64,216
|
|
Adjusted EBITDA(1)
|
$
|
(1,663
|
)
|
|
$
|
2,967
|
|
|
$
|
(6,903
|
)
|
|
$
|
(838
|
)
|
(1)
|
Adjusted EBITDA and adjusted contribution include the impact of a $0.8 million gain during the third quarter of 2018 related to the renewal of our agreement with Lloyds, which contains certain amendments that are retroactively applied as of January 1, 2018.
|
|
Three Months Ended September 30,
|
|
Nine Months Ended September 30,
|
||||||||||||
|
2018
|
|
2019
|
|
2018
|
|
2019
|
||||||||
Revenue
|
$
|
34,582
|
|
|
$
|
56,419
|
|
|
$
|
102,865
|
|
|
$
|
141,137
|
|
Plus:
|
|
|
|
|
|
|
|
||||||||
Consumer Incentives
|
14,002
|
|
|
26,373
|
|
|
45,899
|
|
|
73,981
|
|
||||
Billings
|
$
|
48,584
|
|
|
$
|
82,792
|
|
|
$
|
148,764
|
|
|
$
|
215,118
|
|
|
Three Months Ended September 30,
|
|
Nine Months Ended September 30,
|
||||||||||||
|
2018
|
|
2019
|
|
2018
|
|
2019
|
||||||||
Revenue
|
$
|
34,582
|
|
|
$
|
56,419
|
|
|
$
|
102,865
|
|
|
$
|
141,137
|
|
Minus:
|
|
|
|
|
|
|
|
||||||||
FI Share and other third-party costs(1)
|
17,982
|
|
|
32,470
|
|
|
59,149
|
|
|
79,094
|
|
||||
Delivery costs(2)
|
3,007
|
|
|
3,070
|
|
|
7,509
|
|
|
9,686
|
|
||||
Gross profit(1)
|
13,593
|
|
|
20,879
|
|
|
36,207
|
|
|
52,357
|
|
||||
Plus:
|
|
|
|
|
|
|
|
||||||||
Delivery costs(2)
|
3,007
|
|
|
3,070
|
|
|
7,509
|
|
|
9,686
|
|
||||
Non-cash equity expense included in FI Share(3)
|
—
|
|
|
—
|
|
|
2,519
|
|
|
—
|
|
||||
Amortization of deferred FI implementation costs(3)
|
378
|
|
|
789
|
|
|
1,136
|
|
|
2,173
|
|
||||
Adjusted contribution(1)
|
$
|
16,978
|
|
|
$
|
24,738
|
|
|
$
|
47,371
|
|
|
$
|
64,216
|
|
(1)
|
FI Share and other third-party costs, gross profit and adjusted contribution include the impact of a $0.8 million gain during the third quarter of 2018 related to the renewal of our agreement with Lloyds, which contains certain amendments that are retroactively applied as of January 1, 2018.
|
(2)
|
Stock-based compensation expense recognized in delivery costs totaled $0.2 million and $0.2 million for the three months ended September 30, 2018 and 2019, respectively, and $0.5 million and $0.5 million for the nine months ended September 30, 2018 and 2019, respectively.
|
(3)
|
Non-cash equity expense included in FI Share and amortization of deferred FI implementation costs are excluded from adjusted FI Share and other third party costs as follows (in thousands):
|
|
Three Months Ended September 30,
|
|
Nine Months Ended September 30,
|
||||||||||||
|
2018
|
|
2019
|
|
2018
|
|
2019
|
||||||||
FI Share and other third-party costs
|
$
|
17,982
|
|
|
$
|
32,470
|
|
|
$
|
59,149
|
|
|
$
|
79,094
|
|
Minus:
|
|
|
|
|
|
|
|
||||||||
Non-cash equity expense included in FI Share
|
—
|
|
|
—
|
|
|
2,519
|
|
|
—
|
|
||||
Amortization of deferred FI implementation costs
|
378
|
|
|
789
|
|
|
1,136
|
|
|
2,173
|
|
||||
Adjusted FI Share and other third-party costs
|
$
|
17,604
|
|
|
$
|
31,681
|
|
|
$
|
55,494
|
|
|
$
|
76,921
|
|
|
Three Months Ended September 30,
|
|
Nine Months Ended September 30,
|
||||||||||||
|
2018
|
|
2019
|
|
2018
|
|
2019
|
||||||||
Net loss(1)
|
$
|
(8,368
|
)
|
|
$
|
(7,747
|
)
|
|
$
|
(41,476
|
)
|
|
$
|
(20,571
|
)
|
Plus:
|
|
|
|
|
|
|
|
||||||||
Income tax benefit
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
||||
Interest expense, net
|
254
|
|
|
218
|
|
|
2,995
|
|
|
860
|
|
||||
Depreciation and amortization expense
|
777
|
|
|
1,167
|
|
|
2,471
|
|
|
3,181
|
|
||||
Stock-based compensation expense
|
5,723
|
|
|
7,486
|
|
|
16,968
|
|
|
12,266
|
|
||||
Foreign currency loss
|
256
|
|
|
903
|
|
|
682
|
|
|
1,079
|
|
||||
Amortization of deferred FI implementation costs
|
378
|
|
|
789
|
|
|
1,136
|
|
|
2,173
|
|
||||
Loss on extinguishment of debt
|
—
|
|
|
28
|
|
|
924
|
|
|
51
|
|
||||
Change in fair value of warrant liability
|
(801
|
)
|
|
—
|
|
|
6,760
|
|
|
—
|
|
||||
Non-cash equity expense included in FI Share
|
—
|
|
|
—
|
|
|
2,519
|
|
|
—
|
|
||||
Costs associated with financing events
|
118
|
|
|
123
|
|
|
118
|
|
|
123
|
|
||||
Adjusted EBITDA(1)
|
$
|
(1,663
|
)
|
|
$
|
2,967
|
|
|
$
|
(6,903
|
)
|
|
$
|
(838
|
)
|
(1)
|
Net loss and adjusted EBITDA includes the impact of a $0.8 million gain during the third quarter of 2018 related to the renewal of our agreement with Lloyds, which contains certain amendments that are retroactively applied as of January 1, 2018.
|
|
Three Months Ended September 30,
|
|
Nine Months Ended September 30,
|
||||||||||||
|
2018
|
|
2019
|
|
2018
|
|
2019
|
||||||||
Revenue
|
$
|
34,582
|
|
|
$
|
56,419
|
|
|
$
|
102,865
|
|
|
$
|
141,137
|
|
Costs and expenses:
|
|
|
|
|
|
|
|
||||||||
FI Share and other third-party costs
|
17,982
|
|
|
32,470
|
|
|
59,149
|
|
|
79,094
|
|
||||
Delivery costs
|
3,007
|
|
|
3,070
|
|
|
7,509
|
|
|
9,686
|
|
||||
Sales and marketing expense
|
9,452
|
|
|
11,074
|
|
|
27,915
|
|
|
31,458
|
|
||||
Research and development expense
|
4,097
|
|
|
3,018
|
|
|
12,444
|
|
|
8,741
|
|
||||
General and administrative expense
|
7,925
|
|
|
12,218
|
|
|
23,486
|
|
|
27,558
|
|
||||
Depreciation and amortization expense
|
777
|
|
|
1,167
|
|
|
2,471
|
|
|
3,181
|
|
||||
Total costs and expenses
|
43,240
|
|
|
63,017
|
|
|
132,974
|
|
|
159,718
|
|
||||
Operating loss
|
(8,658
|
)
|
|
(6,598
|
)
|
|
(30,109
|
)
|
|
(18,581
|
)
|
||||
Other income (expense):
|
|
|
|
|
|
|
|
||||||||
Interest expense, net
|
(254
|
)
|
|
(218
|
)
|
|
(2,995
|
)
|
|
(860
|
)
|
||||
Change in fair value of warrant liabilities, net
|
801
|
|
|
—
|
|
|
(6,760
|
)
|
|
—
|
|
||||
Other expense
|
(257
|
)
|
|
(931
|
)
|
|
(1,612
|
)
|
|
(1,130
|
)
|
||||
Total other income (expense)
|
290
|
|
|
(1,149
|
)
|
|
(11,367
|
)
|
|
(1,990
|
)
|
||||
Loss before income taxes
|
(8,368
|
)
|
|
(7,747
|
)
|
|
(41,476
|
)
|
|
(20,571
|
)
|
||||
Net loss
|
$
|
(8,368
|
)
|
|
$
|
(7,747
|
)
|
|
$
|
(41,476
|
)
|
|
$
|
(20,571
|
)
|
|
Three Months Ended September 30,
|
|
Change
|
|
Nine Months Ended September 30,
|
|
Change
|
||||||||||||||||||||||
|
2018
|
|
2019
|
|
$
|
|
%
|
|
2018
|
|
2019
|
|
$
|
|
%
|
||||||||||||||
|
(dollars in thousands)
|
||||||||||||||||||||||||||||
Revenue by solution:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||||
Cardlytics Direct
|
$
|
34,420
|
|
|
$
|
56,419
|
|
|
$
|
21,999
|
|
|
64
|
%
|
|
$
|
101,639
|
|
|
$
|
141,137
|
|
|
$
|
39,498
|
|
|
39
|
%
|
Other Platform Solutions
|
162
|
|
|
—
|
|
|
(162
|
)
|
|
(100
|
)
|
|
1,226
|
|
|
—
|
|
|
(1,226
|
)
|
|
(100
|
)
|
||||||
Total revenue
|
$
|
34,582
|
|
|
$
|
56,419
|
|
|
$
|
21,837
|
|
|
63
|
%
|
|
$
|
102,865
|
|
|
$
|
141,137
|
|
|
$
|
38,272
|
|
|
37
|
%
|
|
Three Months Ended September 30,
|
|
Change
|
|
Nine Months Ended September 30,
|
|
Change
|
||||||||||||||||||||||
|
2018
|
|
2019
|
|
$
|
|
%
|
|
2018
|
|
2019
|
|
$
|
|
%
|
||||||||||||||
|
(dollars in thousands)
|
||||||||||||||||||||||||||||
FI Share and other third-party costs by solution:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||||
Cardlytics Direct
|
$
|
18,275
|
|
|
$
|
31,681
|
|
|
$
|
13,406
|
|
|
73
|
%
|
|
$
|
55,032
|
|
|
$
|
76,921
|
|
|
$
|
21,889
|
|
|
40
|
%
|
Renewal of Lloyds agreement
|
(761
|
)
|
|
—
|
|
|
761
|
|
|
(100
|
)
|
|
(761
|
)
|
|
—
|
|
|
761
|
|
|
(100
|
)
|
||||||
Total Cardlytics Direct
|
17,514
|
|
|
31,681
|
|
|
14,167
|
|
|
81
|
|
|
54,271
|
|
|
76,921
|
|
|
22,650
|
|
|
42
|
|
||||||
Other Platform Solutions
|
90
|
|
|
—
|
|
|
(90
|
)
|
|
(100
|
)
|
|
1,223
|
|
|
—
|
|
|
(1,223
|
)
|
|
(100
|
)
|
||||||
Other components of FI Share and other third-party costs:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||||
Non-cash equity expense included in FI Share
|
—
|
|
|
—
|
|
|
—
|
|
|
n/a
|
|
|
2,519
|
|
|
—
|
|
|
(2,519
|
)
|
|
(100
|
)
|
||||||
Amortization of deferred FI implementation costs
|
378
|
|
|
789
|
|
|
411
|
|
|
109
|
|
|
1,136
|
|
|
2,173
|
|
|
1,037
|
|
|
91
|
|
||||||
Total FI Share and other third-party costs
|
$
|
17,982
|
|
|
$
|
32,470
|
|
|
$
|
14,488
|
|
|
81
|
%
|
|
$
|
59,149
|
|
|
$
|
79,094
|
|
|
$
|
19,945
|
|
|
34
|
%
|
% of revenue
|
52
|
%
|
|
58
|
%
|
|
|
|
|
|
58
|
%
|
|
56
|
%
|
|
|
|
|
|
Three Months Ended September 30,
|
|
Change
|
|
Nine Months Ended September 30,
|
|
Change
|
||||||||||||||||||||||
|
2018
|
|
2019
|
|
$
|
|
%
|
|
2018
|
|
2019
|
|
$
|
|
%
|
||||||||||||||
|
(dollars in thousands)
|
||||||||||||||||||||||||||||
Delivery costs
|
$
|
3,007
|
|
|
$
|
3,070
|
|
|
$
|
63
|
|
|
2
|
%
|
|
$
|
7,509
|
|
|
$
|
9,686
|
|
|
$
|
2,177
|
|
|
29
|
%
|
% of revenue
|
9
|
%
|
|
5
|
%
|
|
|
|
|
|
7
|
%
|
|
7
|
%
|
|
|
|
|
|
Three Months Ended September 30,
|
|
Change
|
|
Nine Months Ended September 30,
|
|
Change
|
||||||||||||||||||||||
|
2018
|
|
2019
|
|
$
|
|
%
|
|
2018
|
|
2019
|
|
$
|
|
%
|
||||||||||||||
|
(dollars in thousands)
|
||||||||||||||||||||||||||||
Sales and marketing expense
|
$
|
9,452
|
|
|
$
|
11,074
|
|
|
$
|
1,622
|
|
|
17
|
%
|
|
$
|
27,915
|
|
|
$
|
31,458
|
|
|
$
|
3,543
|
|
|
13
|
%
|
% of revenue
|
27
|
%
|
|
20
|
%
|
|
|
|
|
|
27
|
%
|
|
22
|
%
|
|
|
|
|
|
Three Months Ended September 30,
|
|
Change
|
|
Nine Months Ended September 30,
|
|
Change
|
||||||||||||||||||||||
|
2018
|
|
2019
|
|
$
|
|
%
|
|
2018
|
|
2019
|
|
$
|
|
%
|
||||||||||||||
|
(dollars in thousands)
|
||||||||||||||||||||||||||||
Research and development expense
|
$
|
4,097
|
|
|
$
|
3,018
|
|
|
$
|
(1,079
|
)
|
|
(26
|
)%
|
|
$
|
12,444
|
|
|
$
|
8,741
|
|
|
$
|
(3,703
|
)
|
|
(30
|
)%
|
% of revenue
|
12
|
%
|
|
5
|
%
|
|
|
|
|
|
12
|
%
|
|
6
|
%
|
|
|
|
|
|
Three Months Ended September 30,
|
|
Change
|
|
Nine Months Ended September 30,
|
|
Change
|
||||||||||||||||||||||
|
2018
|
|
2019
|
|
$
|
|
%
|
|
2018
|
|
2019
|
|
$
|
|
%
|
||||||||||||||
|
(dollars in thousands)
|
||||||||||||||||||||||||||||
General and administration expense
|
$
|
7,925
|
|
|
$
|
12,218
|
|
|
$
|
4,293
|
|
|
54
|
%
|
|
$
|
23,486
|
|
|
$
|
27,558
|
|
|
$
|
4,072
|
|
|
17
|
%
|
% of revenue
|
23
|
%
|
|
22
|
%
|
|
|
|
|
|
23
|
%
|
|
20
|
%
|
|
|
|
|
|
Three Months Ended September 30,
|
|
Change
|
|
Nine Months Ended September 30,
|
|
Change
|
||||||||||||||||||||
|
2018
|
|
2019
|
|
$
|
|
%
|
|
2018
|
|
2019
|
|
$
|
|
%
|
||||||||||||
Delivery costs
|
$
|
203
|
|
|
$
|
176
|
|
|
(27
|
)
|
|
(13
|
)%
|
|
$
|
471
|
|
|
$
|
539
|
|
|
68
|
|
|
14
|
%
|
Sales and marketing expense
|
1,939
|
|
|
1,432
|
|
|
(507
|
)
|
|
(26
|
)%
|
|
5,550
|
|
|
3,091
|
|
|
(2,459
|
)
|
|
(44
|
)%
|
||||
Research and development expense
|
915
|
|
|
638
|
|
|
(277
|
)
|
|
(30
|
)%
|
|
3,141
|
|
|
1,204
|
|
|
(1,937
|
)
|
|
(62
|
)%
|
||||
General and administrative expense
|
2,666
|
|
|
5,240
|
|
|
2,574
|
|
|
97
|
%
|
|
7,806
|
|
|
7,432
|
|
|
(374
|
)
|
|
(5
|
)%
|
||||
Total stock-based compensation expense
|
$
|
5,723
|
|
|
$
|
7,486
|
|
|
1,763
|
|
|
31
|
%
|
|
$
|
16,968
|
|
|
$
|
12,266
|
|
|
(4,702
|
)
|
|
(28
|
)%
|
|
17
|
%
|
|
13
|
%
|
|
|
|
|
|
16
|
%
|
|
9
|
%
|
|
|
|
|
|
Three Months Ended September 30,
|
|
Change
|
|
Nine Months Ended September 30,
|
|
Change
|
||||||||||||||||||||||
|
2018
|
|
2019
|
|
$
|
|
%
|
|
2018
|
|
2019
|
|
$
|
|
%
|
||||||||||||||
|
(dollars in thousands)
|
||||||||||||||||||||||||||||
Depreciation and amortization expense
|
$
|
777
|
|
|
$
|
1,167
|
|
|
$
|
390
|
|
|
50
|
%
|
|
$
|
2,471
|
|
|
$
|
3,181
|
|
|
$
|
710
|
|
|
29
|
%
|
% of revenue
|
2
|
%
|
|
2
|
%
|
|
|
|
|
|
2
|
%
|
|
2
|
%
|
|
|
|
|
|
Three Months Ended September 30,
|
|
Change
|
|
Nine Months Ended September 30,
|
|
Change
|
||||||||||||||||||||||
|
2018
|
|
2019
|
|
$
|
|
%
|
|
2018
|
|
2019
|
|
$
|
|
%
|
||||||||||||||
|
(dollars in thousands)
|
||||||||||||||||||||||||||||
Interest expense
|
$
|
(441
|
)
|
|
$
|
(379
|
)
|
|
$
|
62
|
|
|
(14
|
)%
|
|
$
|
(3,521
|
)
|
|
$
|
(1,337
|
)
|
|
$
|
2,184
|
|
|
(62
|
)%
|
Interest income
|
187
|
|
|
161
|
|
|
(26
|
)
|
|
(14
|
)%
|
|
526
|
|
|
477
|
|
|
(49
|
)
|
|
(9
|
)%
|
||||||
Interest expense, net
|
$
|
(254
|
)
|
|
$
|
(218
|
)
|
|
$
|
36
|
|
|
(14
|
)%
|
|
$
|
(2,995
|
)
|
|
$
|
(860
|
)
|
|
$
|
2,135
|
|
|
(71
|
)%
|
% of revenue
|
(1
|
)%
|
|
—
|
%
|
|
|
|
|
|
(3
|
)%
|
|
(1
|
)%
|
|
|
|
|
|
Three Months Ended September 30,
|
|
Change
|
|
Nine Months Ended September 30,
|
|
Change
|
||||||||||||||||||||||
|
2018
|
|
2019
|
|
$
|
|
%
|
|
2018
|
|
2019
|
|
$
|
|
%
|
||||||||||||||
|
(dollars in thousands)
|
||||||||||||||||||||||||||||
Change in fair value of warrant liabilities
|
$
|
801
|
|
|
$
|
—
|
|
|
$
|
(801
|
)
|
|
(100
|
)%
|
|
$
|
(6,760
|
)
|
|
$
|
—
|
|
|
$
|
6,760
|
|
|
(100
|
)%
|
% of revenue
|
2
|
%
|
|
—
|
%
|
|
|
|
|
|
(7
|
)%
|
|
—
|
%
|
|
|
|
|
|
Three Months Ended September 30,
|
|
Change
|
|
Nine Months Ended September 30,
|
|
Change
|
||||||||||||||||||||||
|
2018
|
|
2019
|
|
$
|
|
%
|
|
2018
|
|
2019
|
|
$
|
|
%
|
||||||||||||||
|
(dollars in thousands)
|
||||||||||||||||||||||||||||
Foreign currency loss
|
$
|
(256
|
)
|
|
$
|
(903
|
)
|
|
$
|
(647
|
)
|
|
253
|
%
|
|
$
|
(682
|
)
|
|
$
|
(1,079
|
)
|
|
$
|
(397
|
)
|
|
58
|
%
|
Loss on extinguishment of debt
|
—
|
|
|
(28
|
)
|
|
(28
|
)
|
|
n/a
|
|
|
(924
|
)
|
|
(51
|
)
|
|
873
|
|
|
(94
|
)
|
||||||
Loss on sale of assets
|
(1
|
)
|
|
—
|
|
|
1
|
|
|
(100
|
)
|
|
(6
|
)
|
|
—
|
|
|
6
|
|
|
(100
|
)
|
||||||
Other expense
|
$
|
(257
|
)
|
|
$
|
(931
|
)
|
|
$
|
(674
|
)
|
|
262
|
%
|
|
$
|
(1,612
|
)
|
|
$
|
(1,130
|
)
|
|
$
|
482
|
|
|
(30
|
)%
|
% of revenue
|
(1
|
)%
|
|
(2
|
)%
|
|
|
|
|
|
(2
|
)%
|
|
(1
|
)%
|
|
|
|
|
|
December 31, 2018
|
|
September 30, 2019
|
||||
Cash and cash equivalents
|
$
|
39,623
|
|
|
$
|
95,184
|
|
Restricted cash
|
20,247
|
|
|
246
|
|
||
Accounts receivable, net
|
58,125
|
|
|
61,691
|
|
||
Working capital
|
72,446
|
|
|
102,941
|
|
||
Total debt
|
46,714
|
|
|
42
|
|
||
Unused available borrowings
|
3,300
|
|
|
40,000
|
|
|
Nine Months Ended September 30,
|
||||||
|
2018
|
|
2019
|
||||
Cash, cash equivalents and restricted cash — Beginning of period
|
$
|
21,262
|
|
|
$
|
59,870
|
|
Net cash (used in) from operating activities
|
(14,300
|
)
|
|
7,357
|
|
||
Net cash used in investing activities
|
(4,185
|
)
|
|
(6,411
|
)
|
||
Net cash from financing activities
|
65,142
|
|
|
35,049
|
|
||
Effect of exchange rates on cash, cash equivalents and restricted cash
|
(107
|
)
|
|
(435
|
)
|
||
Cash, cash equivalents and restricted cash — End of period
|
$
|
67,812
|
|
|
$
|
95,430
|
|
•
|
lack of continued participation by FI partners in our network or our failure to attract new FI partners;
|
•
|
failure by our FI partners to increase engagement with our solutions within their customer bases, improve their customers’ user experience, increase customer awareness, leverage additional customer outreach channels like email or otherwise promote our incentive programs on their websites and mobile applications, including by making the programs difficult to access or otherwise diminishing their prominence;
|
•
|
our failure to offer compelling incentives to our FIs’ customers;
|
•
|
FI partners may elect to use their FI share to fund their Consumer Incentives;
|
•
|
any decline in demand for Cardlytics Direct by marketers or their agencies;
|
•
|
the introduction by competitors of products and technologies that serve as a replacement or substitute for, or represent an improvement over, Cardlytics Direct;
|
•
|
FIs developing their own technology to support purchase intelligence marketing or other incentive programs;
|
•
|
technological innovations or new standards that Cardlytics Direct does not address; and
|
•
|
sensitivity to current or future prices offered by us or competing solutions.
|
•
|
a change in the business strategy;
|
•
|
if there is a competitive reason to do so;
|
•
|
if new technical requirements arise;
|
•
|
consumer concern over use of purchase data;
|
•
|
if they choose to develop and use in-house solutions or use a competitive solution in lieu of our solutions; and
|
•
|
if legislation is passed restricting the dissemination, or our use, of the data that is currently provided to us or if judicial interpretations result in similar limitations.
|
•
|
tailor our solutions so that they that are attractive to businesses in such industries;
|
•
|
hire personnel with relevant industry-vertical experience to lead sales and services teams; and
|
•
|
develop sufficient expertise in such industries so that we can provide effective and meaningful marketing programs and analytics.
|
•
|
dispose of assets;
|
•
|
complete mergers or acquisitions;
|
•
|
incur or guarantee indebtedness;
|
•
|
sell or encumber certain assets;
|
•
|
pay dividends or make other distributions to holders of our capital stock, including by way of certain stock buybacks;
|
•
|
make specified investments;
|
•
|
engage in different lines of business;
|
•
|
change certain key management personnel; and
|
•
|
engage in certain transactions with our affiliates.
|
•
|
our ability to attract and retain marketers, FI partners and bank processor and digital banking provider partners;
|
•
|
the amount and timing of revenue, operating costs and capital expenditures related to the operations and expansion of our business, particularly with respect to our efforts to attract new FI partners to our network;
|
•
|
the revenue mix revenue generated from our operations in the U.S. and U.K.;
|
•
|
delays in the launch of Wells Fargo;
|
•
|
decisions made by our FI partners to increase Consumer Incentives.
|
•
|
FI partners may elect to use their FI share to fund their Consumer Incentives and such election;
|
•
|
changes in the economic prospects of marketers, the industries or verticals that we primarily serve, or the economy generally, which could alter marketers’ spending priorities or budgets;
|
•
|
the termination or alteration of relationships with our FI partners in a manner that impacts ongoing or future marketing campaigns;
|
•
|
the amount and timing of expenses required to grow our business, including the timing of our payments of FI Share and FI Share commitments as compared to the timing of our receipt of payments from our marketers;
|
•
|
changes in demand for our solutions or similar solutions;
|
•
|
seasonal trends in the marketing industry, including concentration of marketer spend in the fourth quarter of the calendar year and declines in marketer spend in the first quarter of the calendar year;
|
•
|
competitive market position, including changes in the pricing policies of our competitors;
|
•
|
exposure related to our international operations and foreign currency exchange rates;
|
•
|
expenses associated with items such as litigation, regulatory changes, cyberattacks or security breaches;
|
•
|
the introduction of new technologies, products or solution offerings by competitors; and
|
•
|
costs related to acquisitions of other businesses or technologies.
|
•
|
maintain and expand our network of FI partners.
|
•
|
build and maintain long-term relationships with marketers and their agencies;
|
•
|
develop and offer competitive solutions that meet the evolving needs of marketers;
|
•
|
expand our relationships with FI partners to enable us to use their purchase data for new solutions;
|
•
|
improve the performance and capabilities of our solutions;
|
•
|
successfully expand our business;
|
•
|
successfully compete with other companies that are currently in, or may in the future enter, the markets for our solutions;
|
•
|
increase market awareness of our solutions and enhance our brand;
|
•
|
manage increased operating expenses as we continue to invest in our infrastructure to scale our business and operate as a public company; and
|
•
|
attract, hire, train, integrate and retain qualified and motivated employees.
|
•
|
the failure of our network or software systems, or the network or software systems of our FI partners;
|
•
|
decisions by our FI partners to restrict our ability to collect data from them (which decision they may make at their discretion) or to refuse to implement the mechanisms that we request to ensure compliance with our legal obligations or technical requirements;
|
•
|
decisions by our FI partners to limit our ability to use their purchase data outside of the applicable banking channel;
|
•
|
decisions by our FIs’ customers to opt out of the incentive program or to use technology, such as browser settings, that reduces our ability to deliver relevant advertisements;
|
•
|
interruptions, failures or defects in our or our FI partners’ data collection, mining, analysis and storage systems;
|
•
|
changes in regulations impacting the collection and use of data, including the use of cookies;
|
•
|
changes in browser or device functionality and settings, and other new technologies, which impact our FI partners’ ability to collect and/or share data about their customers; and
|
•
|
changes in international laws, rules, regulations and industry standards or increased enforcement of international laws, rules, regulations, and industry standards.
|
•
|
localization of our solutions, including adaptation for local practices;
|
•
|
increased management, travel, infrastructure and legal compliance costs associated with having international operations;
|
•
|
fluctuations in currency exchange rates and related effect on our operating results;
|
•
|
longer payment cycles and difficulties in collecting accounts receivable or satisfying revenue recognition criteria, especially in emerging markets;
|
•
|
increased financial accounting and reporting burdens and complexities;
|
•
|
general economic conditions in each country or region;
|
•
|
impact of Brexit;
|
•
|
reduction in billings, foreign currency exchange rates, and trade with the European Union;
|
•
|
contractual and legislative restrictions or changes;
|
•
|
economic uncertainty around the world;
|
•
|
compliance with foreign laws and regulations and the risks and costs of non-compliance with such laws and regulations;
|
•
|
compliance with U.S. laws and regulations for foreign operations, including the Foreign Corrupt Practices Act, the U.K. Bribery Act, import and export control laws, tariffs, trade barriers, economic sanctions and other regulatory or contractual limitations on our ability to sell our software in certain foreign markets, and the risks and costs of non-compliance;
|
•
|
heightened risks of unfair or corrupt business practices in certain geographies and of improper or fraudulent sales arrangements that may impact financial results and result in restatements of financial statements and irregularities in financial statements;
|
•
|
difficulties in repatriating or transferring funds from or converting currencies in certain countries;
|
•
|
cultural differences inhibiting foreign employees from adopting our corporate culture;
|
•
|
reduced protection for intellectual property rights in some countries and practical difficulties of enforcing rights abroad; and
|
•
|
compliance with the laws of foreign taxing jurisdictions and overlapping of different tax regimes.
|
•
|
an acquisition may negatively affect our business, financial condition, operating results or cash flows because it may require us to incur charges or assume substantial debt or other liabilities, may cause adverse tax consequences or unfavorable accounting treatment, may expose us to claims and disputes by third parties, including intellectual property claims and disputes, or may not generate sufficient financial return to offset additional costs and expenses related to the acquisition;
|
•
|
we may encounter difficulties or unforeseen expenditures in integrating the business, technologies, products, personnel or operations of any company that we acquire, particularly if key personnel of the acquired company decide not to work for us;
|
•
|
an acquisition, whether or not consummated, may disrupt our ongoing business, divert resources, increase our expenses and distract our management;
|
•
|
an acquisition may result in a delay or reduction of purchases for both us and the company that we acquired due to uncertainty about continuity and effectiveness of solution from either company;
|
•
|
we may encounter difficulties in, or may be unable to, successfully sell any acquired products or solutions;
|
•
|
an acquisition may involve the entry into geographic or business markets in which we have little or no prior experience or where competitors have stronger market positions;
|
•
|
challenges inherent in effectively managing an increased number of employees in diverse locations;
|
•
|
the potential strain on our financial and managerial controls and reporting systems and procedures;
|
•
|
potential known and unknown liabilities associated with an acquired company;
|
•
|
our use of cash to pay for acquisitions would limit other potential uses for our cash;
|
•
|
if we incur debt to fund such acquisitions, such debt may subject us to material restrictions on our ability to conduct our business as well as financial maintenance covenants;
|
•
|
the risk of impairment charges related to potential write-downs of acquired assets or goodwill in future acquisitions; and
|
•
|
to the extent that we issue a significant amount of equity or convertible debt securities in connection with future acquisitions, existing stockholders may be diluted and earnings (loss) per share may decrease (increase).
|
•
|
pay substantial damages, including treble damages, if we are found to have willfully infringed a third party’s patents or copyrights;
|
•
|
cease developing or selling solutions that rely on technology that is alleged to infringe or misappropriate the intellectual property of others;
|
•
|
expend additional development resources to attempt to redesign our solutions or otherwise develop non-infringing technology, which may not be successful;
|
•
|
enter into potentially unfavorable royalty or license agreements in order to obtain the right to use necessary technologies or intellectual property rights; and
|
•
|
indemnify our FI partners and other third parties.
|
•
|
actual or anticipated fluctuations in our financial condition and operating results;
|
•
|
variance in our financial performance from expectations of securities analysts or investors;
|
•
|
changes in the prices of our solutions;
|
•
|
changes in laws or regulations applicable to our solutions;
|
•
|
announcements by us or our competitors of significant business developments, acquisitions or new offerings;
|
•
|
our involvement in litigation;
|
•
|
our sale of our common stock or other securities in the future;
|
•
|
changes in senior management or key personnel;
|
•
|
trading volume of our common stock;
|
•
|
changes in the anticipated future size and growth rate of our market; and
|
•
|
general economic, regulatory and market conditions.
|
•
|
authorize our board of directors to issue preferred stock without further stockholder action and with voting liquidation, dividend and other rights superior to our common stock;
|
•
|
require that any action to be taken by our stockholders be effected at a duly called annual or special meeting and not by written consent, and limit the ability of our stockholders to call special meetings;
|
•
|
establish an advance notice procedure for stockholder proposals to be brought before an annual meeting, including proposed nominations of persons for director nominees;
|
•
|
establish that our board of directors is divided into three classes, with directors in each class serving three-year staggered terms;
|
•
|
require the approval of holders of two-thirds of the shares entitled to vote at an election of directors to adopt, amend or repeal our amended and restated bylaws or amend or repeal the provisions of our amended and restated certificate of incorporation regarding the election and removal of directors and the ability of stockholders to take action by written consent or call a special meeting;
|
•
|
prohibit cumulative voting in the election of directors; and
|
•
|
provide that vacancies on our board of directors may be filled only by a majority of directors then in office, even though less than a quorum.
|
|
|
|
|
Incorporated by Reference
|
|
|
||||||
Exhibit
|
|
Exhibit Description
|
|
Schedule
/Form
|
|
File
Number
|
|
Exhibit
|
|
Filing Date
|
|
Filed
Herewith
|
3.1
|
|
|
S-1
|
|
333-222531
|
|
3.2
|
|
1/12/2018
|
|
|
|
3.2
|
|
|
S-1
|
|
333-222531
|
|
3.4
|
|
1/12/2018
|
|
|
|
10.1
|
|
|
|
|
|
|
|
|
|
|
X
|
|
31.1
|
|
|
|
|
|
|
|
|
|
|
X
|
|
31.2
|
|
|
|
|
|
|
|
|
|
|
X
|
|
32.1*
|
|
|
|
|
|
|
|
|
|
|
X
|
|
101.ins
|
|
XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.
|
|
|
|
|
|
|
|
|
|
X
|
101.sch
|
|
XBRL Taxonomy Schema Linkbase Document
|
|
|
|
|
|
|
|
|
|
X
|
101.cal
|
|
XBRL Taxonomy Calculation Linkbase Document
|
|
|
|
|
|
|
|
|
|
X
|
101.def
|
|
XBRL Taxonomy Definition Linkbase Document
|
|
|
|
|
|
|
|
|
|
X
|
101.lab
|
|
XBRL Taxonomy Label Linkbase Document
|
|
|
|
|
|
|
|
|
|
X
|
101.pre
|
|
XBRL Taxonomy Presentation Linkbase Document
|
|
|
|
|
|
|
|
|
|
X
|
104
|
|
Cover page formatted as Inline XBRL and contained in Exhibit 101
|
|
|
|
|
|
|
|
|
|
X
|
|
|
|
Cardlytics, Inc.
|
|
|
|
|
|
|
Date:
|
November 12, 2019
|
|
By:
|
/s/ Scott D. Grimes
|
|
|
|
|
Scott D. Grimes
|
|
|
|
|
Chief Executive Officer
(Principal Executive Officer)
|
|
|
|
|
|
Date:
|
November 12, 2019
|
|
By:
|
/s/ David T. Evans
|
|
|
|
|
David T. Evans
|
|
|
|
|
Chief Financial Officer
(Principal Financial and Accounting Officer)
|
“(2)
|
Investments. Borrower may make Investments in the Foreign Subs, in an aggregate amount not to exceed the amount necessary to fund the current operating expenses of the Foreign Subs (taking into account their revenue from other sources); provided that the total of such investments and loans in any fiscal year to all such Foreign Subs shall not exceed $10,000,000. The foregoing shall constitute “Permitted Investments” for purposes of this Loan Agreement.”
|
Borrower:
|
|
Agent and Lender:
|
CARDLYTICS, INC.
|
|
PACIFIC WESTERN BANK
|
|
|
|
/s/ David T. Evans
|
|
/s/ Mykas Degesys
|
David T. Evans
|
|
Mykas Degesys
|
Chief Financial Officer and Head of Corporate Development
|
|
VP
|
1.
|
I have reviewed this Quarterly Report on Form 10-Q of Cardlytics, Inc. (the “registrant”);
|
2.
|
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
|
3.
|
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
|
4.
|
The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
|
a.
|
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
|
b.
|
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
|
c.
|
Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
|
d.
|
Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
|
5.
|
The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
|
a.
|
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
|
b.
|
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
|
Date:
|
November 12, 2019
|
By:
|
/s/ Scott D. Grimes
|
|
|
|
Scott D. Grimes
|
|
|
|
Chief Executive Officer
(Principal Executive Officer)
|
1.
|
I have reviewed this Quarterly Report on Form 10-Q of Cardlytics, Inc. (the “registrant”);
|
2.
|
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
|
3.
|
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
|
4.
|
The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
|
a.
|
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
|
b.
|
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
|
c.
|
Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
|
d.
|
Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
|
5.
|
The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
|
a.
|
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
|
b.
|
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
|
Date:
|
November 12, 2019
|
By:
|
/s/ David T. Evans
|
|
|
|
David T. Evans
|
|
|
|
Chief Financial Officer
(Principal Financial and Accounting Officer) |
1.
|
The Company’s Quarterly Report on Form 10-Q for the period ended September 30, 2019 (the "Report"), fully complies with the requirements of Section 13(a) or Section 15(d) of the Exchange Act; and
|
2.
|
The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
|
Date:
|
November 12, 2019
|
By:
|
/s/ Scott D. Grimes
|
|
|
|
Scott D. Grimes
|
|
|
|
Chief Executive Officer
(Principal Executive Officer)
|
|
|
|
|
Date:
|
November 12, 2019
|
By:
|
/s/ David T. Evans
|
|
|
|
David T. Evans
|
|
|
|
Chief Financial Officer
(Principal Financial and Accounting Officer)
|